PSNL vs. ENZ, XGN, DMTK, BDSX, SERA, AFMD, JATT, TPST, LFVN, and FORA
Should you be buying Personalis stock or one of its competitors? The main competitors of Personalis include Enzo Biochem (ENZ), Exagen (XGN), DermTech (DMTK), Biodesix (BDSX), Sera Prognostics (SERA), Affimed (AFMD), JATT Acquisition (JATT), Tempest Therapeutics (TPST), LifeVantage (LFVN), and Forian (FORA). These companies are all part of the "medical" sector.
Personalis (NASDAQ:PSNL) and Enzo Biochem (NYSE:ENZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.
Personalis currently has a consensus price target of $5.00, suggesting a potential upside of 258.42%. Given Personalis' higher probable upside, analysts clearly believe Personalis is more favorable than Enzo Biochem.
Enzo Biochem has lower revenue, but higher earnings than Personalis.
In the previous week, Personalis had 5 more articles in the media than Enzo Biochem. MarketBeat recorded 6 mentions for Personalis and 1 mentions for Enzo Biochem. Personalis' average media sentiment score of 1.04 beat Enzo Biochem's score of 1.00 indicating that Personalis is being referred to more favorably in the media.
Personalis has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500. Comparatively, Enzo Biochem has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.
61.9% of Personalis shares are owned by institutional investors. Comparatively, 36.9% of Enzo Biochem shares are owned by institutional investors. 4.1% of Personalis shares are owned by insiders. Comparatively, 15.5% of Enzo Biochem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Enzo Biochem received 102 more outperform votes than Personalis when rated by MarketBeat users. However, 65.48% of users gave Personalis an outperform vote while only 56.53% of users gave Enzo Biochem an outperform vote.
Enzo Biochem has a net margin of 99.28% compared to Personalis' net margin of -124.89%. Enzo Biochem's return on equity of -36.71% beat Personalis' return on equity.
Summary
Personalis beats Enzo Biochem on 8 of the 15 factors compared between the two stocks.
Get Personalis News Delivered to You Automatically
Sign up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PSNL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Personalis Competitors List
Related Companies and Tools
